尿激酶联合苯那普利治疗IgA肾病的疗效观察

目的]探讨尿激酶联合苯那普利治疗IgA肾病的临床疗效。方法]140例IgA肾病患按随机数字表法分为对照组(70例)和观察组(70例),观察组患者应用尿激酶加苯那普利联合治疗,对照组单纯应用苯那普利。比较两组的治疗效果。结果]6个疗程后,观察组的尿蛋白量和Scr水平与治疗前相比明显降低,Alb水平和Ccr显著升高(P﹤0.05,0.01),且改善水平显著优于对照组(P﹤0.05);观察组的总有效率为74.3%(52/70),明显高于对照组51.4%(36/70),差异有统计学意义(χ2=7.83,P﹤0.01)。结论]尿激酶联合苯那普利治疗IgA肾病疗效确切,能显著改善肾功能,优于单纯使用苯那普利,值得临床进一步推广应用。

UROKINASE COMBINED WITH BENAZEPRIL IN TREATMENT OF IGA NEPHROPATHY

Objective]To explore the use of urokinase combined with benazepril in treatment of IgA nephropathy.Methods]140 cases of IgA nephropathy patients were randomly divided into control group(n = 70)and observation group(70 cases),the observation group patients with urokinase plus benazepril combined therapy,the control group only benazepril.We compared the therapeutic effects of two groups.Results]After 6 courses of treatment,the observation group in the volume of urine protein and Scr levels compared with before treatment was significantly lower,and the level of Alb and Ccr were significantly increased(P﹤0.05,0.01),and the improved level were significantly better than the control group(P﹤0.05);The total efficiency of the observation group was 74.3%(52/70),which was significantly higher than that of control group(51.4%,36/70),the difference was statistically significant(χ2 = 7.83,P﹤0.01).Conclusion]The urokinase combined with benazepril in treatment of IgA nephropathy curative effect,which can improve the renal function,and was better than simply using benazepril.This method is worthy of further clinical application.